In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk: Riding High on Diabetes

Executive Summary

Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.

You may also be interested in...



Pricing Under The Spotlight As Novo Files Next-Generation Insulins

Novo Nordisk AS says it won’t seek the highest price it believes its next-generation insulins, the ultra-long-acting Degludec and Degludec Plus, could command on the basis of health economic data alone.

Biosimilar Insulin Worth The Effort? For Some, Maybe

With most eyes fixed on the imminent arrival of biosimilar antibodies – billed as the most valuable copy-cat biologics, given originators' high prices – it may be easy to overlook the potential of first-generation biosimilars such as insulin.

Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts

In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV002960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel